Orthocell Limited
ASX: OCC
Orthocell grows 39% with strong product adoption and narrower losses.
(Source: TradingView) 3-Month Performance Profile of OCC on a DTF compared to S&P/ASX 200 (XJO).
Orthocell closed the half-year ended 31 December 2024 on a strong note, fueled by accelerating market adoption of its flagship products. Remplir revenue to Device Technologies surged ~118% YoY, wit
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
